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Tuberous sclerosis complex (TSC) is a multisystem genetic disorder caused by muta-
tions in TSC1 or TSC2. Epilepsy occurs in 80%-90% of affected individuals during their
lifetime, and up to one-third of children with TSC will develop epileptic (infantile)
spasms, for which vigabatrin has been shown to be particularly effective. Epilepsy
severity and epileptic spasms are consistent markers of risk for the development of
intellectual impairment in TSC. Although previous studies demonstrate a bimodal dis-
tribution of intellectual ability in TSC, recent findings suggest a unimodal distribution,
which may reflect a change in IQ distribution over time.We compared 3 large histori-
cal UK cohorts of TSC (n = 331) that show varied distributions of intellectual ability,
first ruling out differences in study methodology. Later-born individuals had a higher
frequency of reported spasms and higher likelihood of vigabatrin administration, but
were less likely to have profound intellectual impairment, compared to the earlier-
born individuals. Our findings suggest that epileptic spasms went undetected in the
older patients and therefore were not treated, leading to a higher occurrence of pro-
found impairment, whereas the later born cohort had better access to treatment.
These findings support the importance of early identification and treatment of sei-
zures in TSC.
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Tuberous sclerosis complex (TSC) is a rare genetic disor-
der caused by a mutation of TSC1 or TSC2 and characterized
by the multisystemic growth of tumor-like lesions called
hamartomas. Cortical tubers and peritubular cortex act as
epileptogenic foci during the early postnatal period and are
associated with an increased risk of epilepsy, intellectual
impairment, and behavioral disturbances. Approximately
90% of individuals with TSC will develop epilepsy, with
seizures usually beginning in the first year of life.1 Epileptic
(infantile) spasms are observed in around half of all cases,
associated with developmental regression and intractable
epilepsy.2
Approximately 50% of individuals develop an intellec-
tual disability, which can range from mild to profound.3
Epilepsy severity and epileptic spasms are a consistent mar-
ker of risk for the development of intellectual impairment in
TSC. Prospective longitudinal studies indicate poor intel-
lectual development in the first 2 years of life in infants with
spasms,4 and a clear impairment in the development of IQ
after the onset of spasms has been demonstrated compared
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to nonspasm seizures.5 The risk of epileptic spasms is corre-
lated with the number of cortical tubers and the presence of
TSC2 versus TSC1 mutations, and contributes to increased
epilepsy severity. In line with this, recent findings suggest a
cascading risk pathway from type of genetic mutation, to
cortical tuber “load,” to epilepsy severity, through to intel-
lectual ability.6
Several studies demonstrate a bimodal distribution of
intellectual ability in TSC. This indicates that most individ-
uals with TSC fall either into the normal ability range or
profoundly impaired range of intellectual ability, and there-
fore that distinct subgroups may exist, for example, based
on type of genetic mutation.7–9 Recent findings, however,
suggest a change to a unimodal distribution in the United
Kingdom.6 The reason for the change in distribution is
unclear and could reflect methodological differences
between cohorts, a decline in IQ in a subset of cases reflect-
ing developmental change, or a true change in IQ distribu-
tion over time. We sought to address this question by
directly comparing the characteristics of 3 large indepen-
dent cohorts of individuals with TSC.
Methods
We directly compare and combine findings from 3
cohorts of TSC:
1. The Wessex cohort (n = 108, date of birth [DoB] 1922–
1995, age = 4.0–75.0 years, M:F = 1:0.9) was ascer-
tained through a 1998 census in the Wessex area of SW
England.10 The average reported age at seizure onset was
28.6 months and 47% of the sample had a history of
epileptic spasms. Data were not available for the propor-
tion that received vigabatrin treatment. Assessment of
intellectual ability was conducted using the Wechsler
Adult Intelligence Scale (WAIS-R), Wechsler Intelli-
gence Scale for Children (WISC-III), Raven’s Coloured
Progressive Matrices, or Vineland Adaptive Behavior
Scale. The median IQ was 75. Estimated IQ was bimod-
ally distributed, with a skewness of 0.14 and a kurtosis
of 1.51; 55.5% had IQ in the normal range, 14% had
mild to severe impairments, and 30.5% had profound dis-
ability.
2. The Cardiff cohort (n = 98; DoB = 1930–1995,
age = 6.0–70.0 years, M:F = 1:0.9), ascertained for
molecular genetic research through adult and pediatric
medical clinics, regional genetics services, and learn-
ing disability services.8 The average reported age of
seizure onset was 43.3 months and 44% of the sample
had a history of epileptic spasms, with 20% of the sam-
ple administered vigabatrin. Assessment of intellectual
level was conducted using the WAIS-R, WISC-III,
Raven’s Coloured Progressive matrices, or Vineland
Adaptive Behavior Scale. The median IQ was 65. Esti-
mated IQ was bimodally distributed with a skewness
of 0.09 and a kurtosis of 1.63; 47.5% had IQ in the
normal range, 20.5% had mild to severe impairments,
and 32% had profound disability.
3. The TS 2000 cohort (n = 125, DoB = 1986–2005,
age = 0.3–21.2 years, M:F = 1:0.9), a prospective lon-
gitudinal study of children in the United Kingdom aged
0-16 years newly diagnosed with TSC between January
2001 and December 2005.6,11 The average age at sei-
zure onset was 13.5 months and 49% of the sample had
a history of epileptic spasms, with 51% of the sample
being administered vigabatrin. Assessment of intellec-
tual level was conducted using the Mullen Scales of
Infant Development and the Vineland Adaptive Behav-
ior Scales. The median IQ was 64. Estimated IQ was
unimodally distributed, with a skewness of 0.83 and a
kurtosis of 0.54; 34.5% had IQ in the normal range,
61.5% had mild to severe impairments, and 1% had
profound disability.
Findings
Although there were some differences in the modes of
ascertainment between the 3 studies (eg, the TS 2000 Study
recruited all newly diagnosed children with TSC over a set
period of time, whereas the Wessex sample included all
cases known to Wessex services, as well as secondarily
ascertained cases), these differences cannot explain the dif-
ferences observed in IQ distribution across cohorts. In addi-
tion, comparable standardized approaches to estimating IQ
were utilized. Moreover, there were no differences in the
sex ratio (v2 = 0.01, p = 0.99), history of epileptic spasms
(v2 = 0.34, p = 0.84), or age at seizure onset (H (2) = 2.02,
p = 0.37) by cohort. When considered as a whole, there was
no significant difference in IQ between studies (F (1,
324) = 1.98, p = 0.14). When considering rates of intellec-
tual disability (normal >70; mild to moderate 35–70; severe
to profound <20–34), significantly fewer individuals in the
TS 2000 cohort had severe to profound disability and more
had mild to moderate disability, compared to the Wessex
and Cardiff cohorts (v2 = 89.91, p < 0.001). Within the
subset of individuals with severe to profound disability,
there was no significant difference across cohorts by sex,
reported age of seizure onset, history of spasms, or type of
mutation (TSC1 versus TSC2; all p > 0.05).
A regression of IQ on date of birth (beta = 0.03,
p = 0.60) and age (beta = 0.04, p = 0.44), revealed that
neither was a significant predictor of IQ. The cohort to
which the participant belonged did not significantly predict
IQ on its own (beta = 0.07, p = 0.22) or when entered
with age (beta = 0.06, p = 0.26) and date of birth
(beta = 0.07, p = 0.23), suggesting that differences in IQ
are not the result of cohort effects.
Distribution of genetic mutations across cohorts
Differences in the distribution of IQ may reflect differ-
ences in the type and location of the genetic mutation across
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the cohorts. Germline mutations were known for 94 partici-
pants from TS 2000 (75 patients had TSC2mutations and 19
had TSC1) and 83 from the Cardiff cohort (70 with TSC2
mutations and 13 with TSC1). Germline mutations were
unavailable from the Wessex cohort. There was no differ-
ence in the frequency of TSC1 versus TSC2 mutations
between the London and Cardiff cohorts (v2 = 0.47,
p = 0.49). There was no difference in the rate of TSC1 or
TSC2 missense mutations, mutations in the TSC1 tuberin
interaction domain, mutations in the TSC2 hamartin binding
domain, TSC2 mutations in the GAP domain, protein trun-
cating TSC2 mutations, or proximal protein truncating
TSC2mutations (see Supplementary Materials, Table S1).
Changes in epilepsy management
An alternative explanation for the change in IQ distribu-
tion is improvement in the management of epilepsy, and, in
particular, epileptic spasms, in the last 2 decades. The pri-
mary approved treatments for children with epileptic
spasms are steroid therapy and vigabatrin. Corticosteroids
were introduced in the late 1940s, whereas vigabatrin was
approved in 1995. In line with this, compared to the Cardiff
cohort, significantly more individuals in the TS 2000 cohort
received vigabatrin treatment (v2 = 22.67, p < 0.001). To
explore this question further, we combined data from all 3
cohorts and stratified by date of birth (before 1950, 1950-
1995, and after 1995). There was a higher rate of vigabatrin
treatment (v2 = 23.72, p < 0.001; Cardiff and TS 2000)
and history of epileptic spasms in those born after 1995
(v2 = 7.72, p = 0.02; all 3 cohorts; Fig. 1).
If epileptic spasms are a risk factor for intellectual impair-
ment, and their effective treatment leads to less severe dis-
ability, we might expect there to be a difference between
cohorts for those that have epileptic spasms only, as the TS
2000 cohort had better access to treatment. Consistent with
this, there were significant differences in IQ by cohort (F
(2,150) = 14.76, p < 0.001) for these individuals; those in
the TS 2000 study had significantly higher mean IQ (61)
compared to those in the Wessex (39; p < 0.001) and Car-
diff (42; p < 0.001) cohorts.
To exclude the possibility that these differences reflected
differences in the age of participants at assessment, we
matched the individuals from the Wessex and Cardiff sam-
ples by age to the TS 2000 cohort (range 25 years, n = 90).
Significant differences in IQ by cohort in individuals with a
history of spasms were retained between TS 2000 (59),
Wessex (43, p = 0.02), and Cardiff (45, p = 0.04).
Discussion
The findings of the current study suggest that although
later-born individuals with TSC had a higher reported fre-
quency of epileptic spasms, this group was less likely to
have profound intellectual impairment. In contrast, those
born earlier were less likely to have epileptic spasms
Figure 1.
Distribution of intellectual ability by history of epileptic spasms and
year of birth across all cohorts: (A) 1922–1950; (B) 1950–1995,
introduction of corticosteroids; (C) 1995 onward, introduction of
vigabatrin.
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recorded, more likely to have profound intellectual impair-
ment, and less likely to have been administered vigabatrin.
These observations are consistent with a model in which
epileptic spasms went undetected or were detected late in
the older patients and therefore were not treated promptly
and/or effectively, leading to a higher occurrence of pro-
found impairment (and therefore a bimodal distribution of
IQ in TSC).
This hypothesis must be tested directly. For example, it
can be postulated that in countries where vigabatrin is not
yet available, a bimodal distribution would still be observed.
In addition, the possibility that there may be intellectual
decline later in development cannot be ruled out. Declines
in IQ have been reported in subsets of infants12 and children
with TSC,13 but intellectual ability appears to be stable in
most individuals after early childhood. Future analyses of
longitudinal cohorts into adulthood are important to reveal
whether such subgroups emerge with development and what
processes are related to these changes.
Although detection and treatment of epileptic spasms
may be important in determining risk for severe to profound
intellectual impairment, other risk factors should not be
overlooked. History of epileptic spasms is consistently
linked to lower intelligence in univariate analyses, yet mul-
tifactorial analyses that are able to test the joint effects of
several influencing factors have suggested that age at sei-
zure onset is the sole variable for independently predicting
intellectual outcome.4,14,15 Thus other types of epilepsy,
including focal seizures, occurring early in life necessitate
prompt management.16,17 It is likely that intellectual devel-
opment in TSC is determined by a complex and dynamic
interaction between several risk factors, including number,
location, and relative proportion of cortical tubers and type
of genetic mutation, in addition to certain features indexing
epilepsy severity.6,14
These findings have implications for the identification
and prevention of the epilepsy-related risk factors that are
involved in shaping intellectual development in TSC. This
proposition is timely given recent advances in our under-
standing of the pathophysiology and treatment of early
onset epilepsy in TSC. Clinical seizures are preceded by
abnormalities on electroencephalography (EEG) record-
ings, and preventative treatment of epileptiform discharges
may alter the evolution to clinically evident subtle partial
seizures and spasms, which may be difficult for parents to
identify.18,19 For example, infants treated with vigabatrin
based on identification of paroxysmal activity on EEG
before the onset of clinical seizures had better cognitive out-
come at 24 months of age, compared to those treated post-
seizure onset,20 work that is being continued within the
EPISTOP project (www.epistop.eu). In addition, patients
diagnosed with TSC preseizure onset have a lower preva-
lence of refractory seizures and severe developmental dis-
ability, compared to those diagnosed postseizure onset,
despite no regular surveillance EEG.21
Several clinical trials are ongoing that are focused on neu-
rocognitive outcome in TSC based on identified risk factors,
for example, using mammalian target of rapamycin (mTOR)
inhibitors that target the downstream effect of the primary
mutation (ClinicalTrials.gov Identifier: NCT01289912),
through to parent-based intervention (NCT03422367), and
identification of EEG biomarkers of early versus delayed
vigabatrin treatment in infants with TSC (NCT02849457).
The results of these large-scale longitudinal and interven-
tional studies of TSC are eagerly awaited. Future work that
systematically measures the separate and combined effects
of candidate risk factors in neurocognitive development are
required to guide routine surveillance and treatment strate-
gies and to improve longer-term outcome in TSC.
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Table S1. Cohort comparisons of mutation frequency by
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